EA
AVDL

Emerald Acquisition’s Avadel Pharmaceuticals AVDL Stock Holding History

Emerald Acquisition’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$4.19M Sell
337,871
-270,096
-44% -$3.53M 0.01% 1309
2016
Q2 		$6.53M Buy
+607,967
New +$6.48M 0.01% 1175

Other funds holding AVDL

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.94% 1-Year Est. Return

Emerald Acquisition's AVDL Position: Q3 2016 in Review

Emerald Acquisition reduced its Avadel Pharmaceuticals (AVDL) stake by 44% in Q3 2016, selling an estimated $3.53M and leaving 337,871 shares worth $4.19M. The position accounts for 0.01% of the portfolio, ranked #1309.

Emerald Acquisition first reported a position in AVDL in Q2 2016 and has held it in 2 quarters since. The position peaked at $6.53M in Q2 2016. 87 funds tracked by Wall St. Rank hold AVDL as of Q3 2016.

  • Emerald Acquisition held 337,871 shares of Avadel Pharmaceuticals worth $4.19M as of Q3 2016.
  • Emerald Acquisition sold 270,096 Avadel Pharmaceuticals shares in Q3 2016, an estimated $3.53M.
  • Avadel Pharmaceuticals made up 0.01% of Emerald Acquisition's portfolio in Q3 2016, its #1309 holding.
  • Emerald Acquisition first reported a position in Avadel Pharmaceuticals in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's Avadel Pharmaceuticals position peaked at $6.53M in Q2 2016.
  • 87 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.